Article
Biochemistry & Molecular Biology
Cong Zhao, He Zhao, Chun-Cheng Zhang, Xiao-Hui Yang, Kang Chen, Yang Xue, Qian Li, Shu-Ying Deng, Hui-Zhen Cai
Summary: Several studies have shown the effectiveness of Lycium barbarum polysaccharide (LBP) in treating type 2 diabetes. However, the exact mechanism of how LBP alleviates diabetes through GLP1 has not been adequately elucidated.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2023)
Review
Immunology
Syed Faizan Mehdi, Suma Pusapati, Muhammad Saad Anwar, Durga Lohana, Parkash Kumar, Savitri Aninditha Nandula, Fatima Kausar Nawaz, Kevin Tracey, Huan Yang, Derek LeRoith, Michael J. Brownstein, Jesse Roth
Summary: Inflammation is involved in many chronic conditions and stimulates the release of pro-inflammatory cytokines and immune cells. GLP-1 levels are associated with disease severity and can serve as markers of inflammation. Previous studies have investigated the anti-inflammatory properties of oxytocin, hCG, ghrelin, alpha-MSH and ACTH, while the anti-inflammatory effects of GLP-1 have only recently been recognized. GLP-1 has been shown to be beneficial in treating type-2 diabetes, metabolic syndrome, and hyperglycemia by reducing inflammation and cell death.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Chemistry, Medicinal
Neng Jiang, Lin Jing, Qing Li, Sibiao Su, Qimeng Yang, Feng Zhou, Xinyu Chen, Jing Han, Chunli Tang, Weizhong Tang
Summary: Dual activation of the glucagon receptor (GCGR) and glucagon-like peptide 1 receptor (GLP-1R) can potentially lead to effective therapy for diabetes and obesity. Novel peptides with dual activity on GLP-1R and GCGR were discovered through rational design, with xGLP/GCG-15 showing promising anti-obesity and anti-diabetic effects in preclinical studies.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Cardiac & Cardiovascular Systems
Xuefei Liu, Kaushik P. Patel, Hong Zheng
Summary: The study reveals that activation of renal sympathetic nerves contributes to the blunted diuretic and natriuretic effects of GLP-1 in HFD obese rats. The renal nerve-neprilysin-GLP-1 pathway is involved in renal dysfunction during obesity that leads to hypertension.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Article
Pharmacology & Pharmacy
Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li, Nigel H. Greig
Summary: Chronic neuroinflammation is a key feature of neurodegenerative diseases, and targeting this inflammation has not been effectively utilized in clinical treatments. The risk of inflammation and neurodegenerative diseases is associated with type 2 diabetes and insulin resistance, suggesting that alleviating diabetes pathology may help treat neuroinflammation and neurodegeneration. GLP-1 is a hormone that promotes healthy insulin signaling and has shown anti-inflammatory, neurotrophic, and neuroprotective properties in preclinical neurodegenerative disease models.
PHARMACOLOGICAL RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Masoud Nouri-Vaskeh, Neda Khalili, Amirreza Khalaji, Pouya Behnam, Leila Alizadeh, Sara Ebrahimi, Neda Gilani, Mehdi Mohammadi, Seyed Alisalar Madinehzadeh, Mohammad Zarei
Summary: This study found that circulating levels of GLP-1 were lower in patients with liver cirrhosis compared to healthy controls, and were associated with the severity of liver disease.
ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY
(2023)
Article
Chemistry, Medicinal
Yongliang Yuan, Zhiming Yan, Qifang Lao, Neng Jiang, Shuangmin Wu, Qinpei Lu, Jing Han, Songfeng Zhao
Summary: The development of a unimolecular triple agonist peptide targeting GLP-1, glucagon, and Y2 receptors shows great potential as a novel anti-obesity and anti-diabetic agent. This peptide, 3b, demonstrated potent activity in reducing food intake without causing nausea and had better effects on lipid metabolism, body weight, and glycemic control compared to other agonist counterparts. Targeting GLP-1R, GCGR, and Y2R with a unimolecular triple agonist peptide offers a promising route for developing new treatments for obesity and T2DM.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Integrative & Complementary Medicine
Li Qiang, Yang Qimeng, Han Jing, Liu Xiaohan, Fu Junjie, Yin Jian
Summary: Peptide dual agonists that target both GLP-1R and GCGR receptors have emerged as potential therapeutics for treating type 2 diabetes with obesity. O-GlcNAcylation was shown to improve the stability of a dual GLP-1R/GCGR agonist, leading to significant weight loss and hypoglycemic effects.
CHINESE JOURNAL OF NATURAL MEDICINES
(2022)
Article
Biochemistry & Molecular Biology
Xiaolong Zhang, Yuchen Cai, Zhihong Yao, Heng Chi, Yan Li, Jingjing Shi, Zhongbo Zhou, Lidan Sun
Summary: A novel GLP-1R/GCGR dual agonist, OXM-7, was discovered and shown to have potent and balanced efficacy on both receptors. In mice models, OXM-7 exhibited promising effects on glycemic control, weight loss, lipid metabolism, and hepatic steatosis reversal.
Article
Endocrinology & Metabolism
Shiau Chin Chong, Norlela Sukor, Sarah Anne Robert, Kim Fong Ng, Nor Azmi Kamaruddin
Summary: This study aimed to resolve conflicting findings about GLP-1 levels in different glucose tolerance states among Malay, Chinese, and Indian ethnicities. The results showed that GLP-1 levels were higher in T2DM and pre-DM compared to NGT, suggesting a possible adaptive compensatory response. Among the three ethnic groups, Indians had the highest levels of GLP-1 and insulin resistance, supporting the notion of an adaptive compensatory secretion of GLP-1.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Pharmacology & Pharmacy
Baocheng Xie, Shichun Chen, Yongxiang Xu, Weichao Han, Runkai Hu, Minyi Chen, Yusheng Zhang, Shaobo Ding
Summary: Diabetes mellitus and osteoporosis are closely related, and GLP-1RAs may help in controlling blood sugar levels and promoting bone formation, but more research is needed to clarify their specific effects and mechanisms.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Tiina Vesterinen, Elina Peltola, Helena Leijon, Paeivi Hannula, Heini Huhtala, Markus J. Makinen, Lasse Nieminen, Elina Pirinen, Mikko Ronty, Mirva Soderstrom, Pia Jaatinen, Johanna Arola
Summary: This study found that the lack of GLP-1R expression in insulinomas is associated with metastatic disease and impaired prognosis. GLP-1R expression could be a useful biomarker in estimating the metastatic potential and prognosis of surgically treated patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Maria F. Fernandes, Michelle Tomczewski, Robin E. Duncan
Summary: This study found that chronic inflammation leads to reduced GLP-1 secretion and impaired GSIS. Lysophosphatidic acids (LPAs) inhibit GLP-1 secretion in vitro and in vivo through G alpha(i)-coupled LPAR1/3 signaling, linking inflammation with impaired GSIS.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, Research & Experimental
Chun Han, Yuqing Sun, Qimeng Yang, Feng Zhou, Xinyu Chen, Lintao Wu, Lidan Sun, Jing Han
Summary: The study identified a novel dual GLP-1R and GCGR agonist, which showed potential for treatment of diabetes and obesity by improving glucose control in vivo. The development of peptide 2c with balanced GLP-1R and GCGR activations and potent effects on glucose control suggests a promising new approach for antidiabetic and/or antiobesity drug development.
MOLECULAR PHARMACEUTICS
(2021)
Article
Medicine, Research & Experimental
Joice de Fatima Laureano Martins, Thaiany Goulart de Souza-Silva, Hudsara Aparecida de Almeida Paula, Viviane da Cruz Rafael, Sirlene Souza Rodrigues Sartori, Celia Lucia de Luces Fortes Ferreira
Summary: This study evaluated the potential effects of yacon-based product on glycemic profile and intestinal health in postmenopausal rats. The results showed that the product did not cause liver damage and gastrointestinal disorders, and it had beneficial effects on the morphology and function of the intestinal mucous of rats. It also had the potential to indirectly modulate glycemic and insulinemic profiles, weight gain, and body fat percentage.